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Abstract
Multiple sclerosis (MS) is a highly disabling neurodegenerative autoimmune condition in
which an unbalanced immune response plays a critical role. Although the mechanisms
remain poorly defined, helminth infections are known to modulate the severity and progres-
sion of chronic inflammatory diseases. The tyrosine kinase receptors TYRO3, AXL, and
MERTK (TAM) have been described as inhibitors of the immune response in various inflam-
matory settings. We show here that patients with concurrent natural helminth infections and
MS condition (HIMS) had an increased expression of the negative regulatory TAM receptors
in antigen-presenting cells and their agonist GAS6 in circulating CD11bhigh and CD4+ T cells
compared to patients with only MS. The Th17 subset was reduced in patients with HIMS
with a subsequent downregulation of its pathogenic genetic program. Moreover, these
CD4+ T cells promoted lower levels of the co-stimulatory molecules CD80, CD86, and CD40
on dendritic cells compared with CD4+ T cells from patients with MS, an effect that was
GAS6-dependent. IL-10+ cells from patients with HIMS showed higher GAS6 expression
levels than Th17 cells, and inhibition of phosphatidylserine/GAS6 binding led to an expan-
sion of Th17 effector genes. The addition of GAS6 on activated CD4+ T cells from patients
with MS restrains the Th17 gene expression signature. This cohort of patients with HIMS
unravels a promising regulatory mechanism to dampen the Th17 inflammatory response in
autoimmunity.
Author summary
Helminths have co-evolved with human civilization, and the rapid exclusion from their
environment, in the last few decades, has tremendously affected the immune development
and regulation. Moreover, several epidemiological studies have shown an inverse correla-
tion between the exposure of these organisms and the development of autoimmunity in
industrialized countries. In this sense, helminth therapy appears to be a promising
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concept to oppose chronic inflammatory and autoimmune diseases because they are mas-
ter manipulators of host immunity, albeit the mechanisms remain poorly defined. For this
reason, it is essential to decipher the main regulatory pathways to hijack the immune
response in the absence of parasite infection. Our research described how helminth infec-
tion promotes regulatory mechanisms based on the tyrosine kinase TYRO3, AXL,
MERTK (TAM) receptors, and their ligand GAS6 to dampen Th17 development and the
inflammatory response in patients with multiple sclerosis (MS), a neurodegenerative auto-
immune disorder. We show here that GAS6 plays a critical role in the regulation of pro-
inflammatory cytokines, transcriptional programs, and plasticity of IL-17 subset. Our
work substantiates the hypothesis that enhancing the TAM axis in a manner similar to
helminth infection could be a promising alternative for autoimmune diseases.
Introduction
Multiple sclerosis (MS) is a chronic demyelinating and neurodegenerative autoimmune dis-
ease of the central nervous system (CNS) that frequently begins between 20 and 40 years of
age. MS affects an estimated 2.5 million people worldwide and represents the second most
common cause of nervous system disability in young adults after traumatic brain injury. The
etiology of MS is complex and comprises both genetic and environmental risk factors. A strong
correlation exists with certain HLA II alleles (mainly HLA-DRB1�15:01 and DRB5�01:01),
pointing directly to CD4+ T cells as key players in MS [1–3]. Evidence shows that both Th1
and Th17 subsets are necessary for both the onset and progression of the disease. Th1 and
Th17 cells mediate their pathogenic effect through a robust secretion of pro-inflammatory
cytokines (eg, IL-17, IFN-γ, GM-CSF, TNF-α), which in turn activates resident microglia,
astrocytes, infiltrating macrophages, and dendritic cells (DCs) recruited from the periphery,
promoting a pro-inflammatory milieu with the synthesis of cytotoxic reactive oxygen and
nitrogen species (ROS and RNS) [4–6]. One of the most striking illustrations of the impor-
tance of the environment in MS pathogenesis is its geographic distribution; prevalence rates
are increased in high latitude regions yet uncommon near the equator [7]. Furthermore, indi-
viduals who move from a low-risk to a high-risk area, especially before the age of 15, show sim-
ilar incidences to host country populations, suggesting the presence of either a protective
factor in the region of origin or a harmful factor in the adopted region [8]. During the last cen-
tury in developed countries, a significant increase in autoimmune and allergic diseases has
been observed [9] that cannot be attributed to significant genetic alterations, implying a critical
environment change occurred in this period. Candidates likely to be responsible for this effect
in MS, alone or in combination with others, include sunlight-UV exposure with or without
Vitamin D deficiency, viral infections, and cigarette smoking. Factors may not only influence
disease onset at any time in the life of an individual but also affect relapse rates in patients pre-
senting relapsing-remitting forms of MS [10].
The originally formulated “hygiene hypothesis,” later reformulated as the “old friends
hypothesis,” establishes the necessity of the development of a properly “educated” immune sys-
tem during our early years that is allowed by challenges from an array of harmless microbes
[11,12]. Although many helminths could be harmful to their hosts in high burden, the long-
standing helminth-host coexistence supports the concept that evolutionary forces shaped a
balanced immune relationship in the context of Th2 response controlling also associated
chronic inflammatory responses [13–16]. The type 2 immunity elicited against helminth tends
to limit parasite burden and tissue damage, but also primes the immune response with
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regulatory programs [17]. In the last few decades, the incidence of helminth and bacterial
infections has abruptly dropped in industrialized countries, and multiple epidemiological
studies have shown an inverse correlation between the exposure of these organisms and the
development of autoimmunity, bringing helminthic immunology under the spotlight [9,18–
20]. Correale et al reported that natural helminth infections protect the course of MS in
humans as evidenced by a reduction in the number of relapses, minimal changes in disability
scores, and a significant decrease in the number of new or enlarging T2 lesions and gadolin-
ium-enhancing lesions compared with uninfected individuals with MS [21]. The protection
conferred by parasite infection was associated with IL-10 and TGF-β secretion, the increased
suppressive activity of CD4+CD25+FOXP3+ T cells mediated by cell contact, and the induction
of B regulatory cells [21,22]. Patients treated with anthelmintic drugs presented a significant
increase both in the number of relapses and disability scores [23].
Considering the critical role of negative regulatory pathways in avoiding chronic inflamma-
tion and autoimmunity, we focus on a subfamily of receptor tyrosine kinases (TKR) that
involves TYRO3, AXL, and MERTK (TAM) [24]. These receptors showed a preponderant role
in innate immune response and their genetic ablation leads to an impaired immune response
with exacerbated autoimmune features [25]. The engagement of these receptors by their
ligands, PROS1 and GAS6, limit the magnitude and time course of the inflammatory response
that can ensure a return to the baseline [26,27]. The endogenous agonists, PROS1 and GAS6,
are Gla domain-containing proteins capable of binding exposed phosphatidylserine (PtdSer)
in a Ca2++-dependent manner. We have previously shown that T cells activation induces
PROS1 and externalizes PtdSer, thereby triggering TAM receptors on dendritic cells (DCs) to
dampen the inflammatory response [27]. Recently, we have also elucidated that TYRO3
and PROS1 are key regulators of type 2 immunity in mouse models of allergy or helminth
(Nippostrongilus brasiliensis) infection [28]. Finally, Nassar et al highlighted the essential role
of GAS6 promoting tolerance in oral mucosa, as its absence leads to an imbalance in Th17 and
Treg cells [29]. In the present work, we uncovered that helminth infections differentially mod-
ulate the expression of TAM receptors and ligands, and consequently the balance of Th17
response in patients with MS. We discovered that CD4+ T cells from patients with MS and
concurrent natural helminth infections (HIMS) contained a lower percentage of Th17 cells as
well as lineage-specific related genes and dampened DCs activation in a GAS6-dependent




This study was approved by the Institutional Ethics Committee of the Raul Carrea Institute for
Neurological Research (FLENI) and the Institutional Ethics Committee of the National Acad-
emy of Medicine (IMEX-ANM). All study participants provided written informed consent for
the collection of blood samples and subsequent sample analysis.
Patients and sample collection
The present study included 3 clinical groups, 31 healthy volunteers (HC, healthy control), 29
patients with multiple sclerosis (MS), and 18 patients with chronic helminth-infection and
diagnosis of clinically definite relapsing-remitting MS criteria according to Poser’s or McDon-
ald criteria [30,31]. Patients were recruited from a larger cohort of 1732 regularly followed
patients with MS and were typical in all respects with the exception of eosinophilia. Any
patient with MS with a high eosinophil count was included in the study. MS diagnosis
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preceded parasitic intestinal infection diagnosis by 38.3 + 7.3 months (range 18–45 months).
Helminth-infected multiple sclerosis patients (HIMS) were confirmed by stool examination,
eosinophilia, and IgE levels. Fecal samples were analyzed for parasite eggs, species identifica-
tion, and the number of eggs per gram of feces, prepared by formalin-ether sedimentation.
The HIMS subjects were infected with Strongyloides stercolaris,Hymenolepis nana, Enterobius
vermicularis, Ancylostoma duodenale, Ascaris lumbricoides, or Trichuris trichura without
undergoing anti-parasitic treatment at the starting point of the study. The presence of
other endemic parasitoses, including trypanosomiasis, leishmaniasis, amebiasis, giardiasis, and
toxoplasmosis, were excluded using microscopic examination and serological testing. In all
parasite-infected patients with MS, the eosinophilia was not present during the previous two
years. Five of the parasite-infected patients with MS enrolled here were previously reported
[21].
Both eosinophil counts and stool examinations examined in uninfected MS subjects were
found to be negative at study entry and throughout the entire study. Blood collection was
performed during the remission phase of the disease. Blood draws were performed at least 90
days after a relapse or a course of steroids. No significant differences in age or gender propor-
tion were observed among groups (Table 1). The EDSS score was significant lower in patients
with HIMS (0.33 ± 0.188) compared with patients with MS(1.75 ± 0.185, p<0.0001) and all
patients with MS and around the half of those with HIMS were under IFN-β treatment
(Table 1).
Table 1. Clinical characteristics of the cohorts.


















2 years before entry NA 0.83 + 0.40 0.80 + 0.38
Eosinophil count/mm3 NA 278.9 ± 114.5 1576 ± 250.5 ���
IgE titers IU/mL NA 448 ± 206.2 1667 ± 675.2 ���










Mean +/- SD NA 1.75 ± 0.1853 0.3333 ± 0.188 ����









5.115 ± 0.340 #




1.487 ± 0.186 ###
0.1253 ± 0.028
4.277 ± 0.479
SD = standard deviation; yr = year, NA = No applicable
��� p< 0.001 HIMS vs MS
���� p< 0.0001 HIMS vs MS
# p< 0.05 MS vs Control
## p< 0.0001 MS vs Control
### p< 0.05 HIMS vs MS
https://doi.org/10.1371/journal.ppat.1009176.t001
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Haematological analysis
Cell counts and varying levels of each white fraction was measured using an Abacus Junior Vet
veterinary automated analyzer (Vienna, Austria).
Peripheral blood mononuclear cells (PBMCs) isolation and
characterization of TAM receptors expression by flow cytometry
PBMCs from patients and healthy volunteer controls were obtained by centrifugation as previ-
ously described [27,32]. Briefly, the anti-coagulated blood sample was first diluted ½ volume/
volume and centrifuged at low speed to separate platelet-rich plasma (200g for 10 min). The
PBMCs were isolated from the cellular fraction by density gradient centrifugation employing
Ficoll Paque Plus (GE Healthcare, Marlborough, MA, USA) following the standard protocol.
Washed PBMCs were cryopreserved in 90% fetal bovine serum (FBS, Thermofisher Scientific,
Argentina) plus 10% dimethyl sulfoxide (Sigma Aldrich, St. Louis, MO, USA), and stored in
liquid nitrogen until use. TYRO3, AXL, and MERTK expression were analyzed in CD11bhigh
monocytes, CD1chigh dendritic cells (DCs), and CD4+ T cells compartment from cryopre-
served PBMCs. Briefly, cells were thawed and washed first with PBS followed by PBS plus 2%
FBS. After washing, cells were blocked in PBS plus 5% FBS for 30 minutes on ice and then
incubated with appropriate antibody combinations against human CD11b-PercP/Cy5.5 (clone
M1/70), CD4-APC/Cy7 (clone OKT4), and CD1c-PE/Cy7 (clone L161) from BioLegend for
30 minutes on ice. Rabbit anti-human TYRO3 (Novus Biological), biotin-conjugated goat
anti-human AXL, and APC anti-human MERTK mAb IgG1 (R&D Systems) were used to eval-
uate TAM receptor expression after fixation and permeabilization (Cytofix/Cytoperm Kit, BD
Bioscience, San Diego, CA, USA). Donkey anti-rabbit AF488 and PE-Streptavidin (Biolegend)
were used as detection signals for TYRO3 and AXL, respectively. Cells were acquired using a
FACS Canto I (Becton Dickinson). All analysis was carried out with FlowJo software (Tree
Star Inc.).
In vitro expansion of Th-subsets and intracellular IL-17, IFN-γ, IL-10,
IL-13 and IL-4 determination
PBMCs were cultured in 24-well plates and stimulated with coated anti-CD3 (1μg/mL) and sol-
uble anti-CD28 (1μg/mL). Fresh complete medium (RPMI-1640 supplemented with 10% FCS,
1% penicillin-streptomycin) was added at day 7. After expansion, cells were harvested at days 7,
10, or 17 and were incubated in ionomycin (1μg/mL), PMA (50nM), and Golgi Stop (BD Bio-
sciences) at 37˚C for 4 hours (h). Cells were washed with PBS, stained for viable cells with Zom-
bie Violet 421 (Fixable Viability Dye), and fixed with Cytofix (BD Biosciences). Cells were
permeabilized and incubated with anti-CD4-PE/Cy7 along with polyclonal rabbit anti-GAS6 or
anti-PROS1-FITC for all subsets while anti-IFNγ-Alexa Fluor647, anti-IL-17-PE, anti-IL-10-PE,
anti-IL-13-PE, and anti-IL-4-PE were utilized for each Th-subset, respectively. Donkey anti-
rabbit AF647 were used as secondary antibody for GAS6 determination. Data were acquired
using FACS Canto I (BD Biosciences) and analyzed using FlowJo software (Tree Star Inc.)
Factor analysis of mixed data
In order to study the similarities between the MS and HIMS cohorts and the relationships with
qualitative and quantitative variables, dimensionality reduction using factor analysis mixed
data (FAMD) was performed. FAMD were computed in RStudio 3.5.3 using missMDA and
FactoMineR packages. First NA missing values were imputed and categorical and continuous
variables were detected automatically. Eigenvalues were then visualized, and the percentage of
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variances was explained by each principal component. Graphics and clustering analysis were
performed using factoextra and autoEDA packages.
In vitro differentiation of monocyte-derived DCs
Monocyte-derived DCs were generated from PBMCs as previously described [32]. CD14+
monocytes were isolated from PBMCs using the EasySep Human CD14 positive selection kit
(StemCell Tech, Vancouver, Canada) following manufacturer’s instructions. 1 x 106 Isolated
CD14+ cells were cultured in a 6-well plate with 1.5 mL of complete RPMI medium, 300 U/mL
of IL-4 (R&D Systems), 450 U/mL of GMCSF (R&D Systems) at 37˚C and 5% CO2. Cytokine
supplementation was performed again on day 3 by adding 1 mL RPMI-1640 supplemented
with 10% FCS, 1% penicillin-streptomycin, 900 U/mL of IL-4 and 1350 U/mL GM-CSF.
Monocyte-derived DCs were harvested on day 7. Recombinant cytokines were purchased
from R&D Systems (Minneapolis, MN, USA).
Mixed lymphocyte reaction (MLR) and GAS6 blocking
Human CD4+ T cells were obtained by negative selection (STEMCELL, USA) and co-cultured
with human monocyte derived-DCs generated as described above at a 5:1 ratio for 72 h. When
indicated, anti-GAS6 blocking antibody and the corresponding isotype control (R&D Systems)
were added on day 0 of co-culture. On day 3, co-stimulatory markers on DC were evaluated by
FACS. The activation markers were characterized by cell surface staining employing the
appropriate combination of directly conjugated antibodies against human CD11c-PerCP/
Cy5.5 (clone 3.9; BioLegend), HLA-DR-FITC (Clone L243; BioLegend), CD80-PE (Clone
2D10; BioLegend), CD40-PE/Cy7 (Clone 5C3; BioLegend) and CD86-biotin (Clone IT2.2;
BioLegend) in combination with DyLight 649-conjugated streptavidin (BioLegend). Viability
was assessed with Fixable Viability Dye eFluor 780 (e-Bioscience). After washing, cells were
fixed with Cytofix/Cytoperm kit (BD Bioscience, San Diego, CA, USA). Cells were acquired
using a FACS Canto I cytometer (Becton Dickinson), and all analysis was carried out with
FlowJo software (Tree Star, Inc.).
Quantitative PCR (qPCR)
For gene expression analysis, sorted CD4+ T cells (negative selection) were stimulated with
1μg/mL of plate-bound anti-CD3 and 1μg/mL soluble anti-CD28 (Life Technologies, Carlsbad,
CA, USA) for 5 days. When indicated, 1 μg/mL of purified Annexin V (Biolegend) or 2 μg/mL
anti-GAS6 blocking antibody and the corresponding isotype control (R&D Systems) were
added on day 0 of co-culture. Treatment with 50 nM of recombinant human GAS6 (R&D Sys-
tems) was also performed every 2 days during 5 days when indicated. Cells were washed and
then harvested with Trizol (Life Technologies, Carlsbad, CA, USA) following manufacturer’s
instructions. Reverse transcription was performed using 100 ng of RNA in 20 μL of reaction
volume by employing iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Real time
PCR reactions were assessed using 1 μL of cDNA in 10 μL of reaction volume by employing
SsoAdvanced universal SYBR Green mix and CFX-Connect equipment (Bio-Rad, Hercules,
CA, USA). Primers used in this study are listed in supplementary S1 Table. The reaction was
normalized to housekeeping gene expression levels, and the specificity of the amplified prod-
ucts was checked through analysis of dissociation curves. To generate heat maps, qCT values
obtained by 2ΔCt method were normalized to reference values (non-activated control or iso-
type conditions) and transformed by log10 function to scale up intergenic expression differ-
ences. Numbers inside colored squares are the mean value from each group in a given
condition.
PLOS PATHOGENS GAS6 axis controls Th17 development
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1009176 December 21, 2020 6 / 22
Statistical analysis
Data are expressed as mean ± SEM. The Shapiro-Wilk test was used to define state normality
and equal variance. Significant differences were determined by one-way analysis of variance
(ANOVA) followed by Fisher multiple comparison test. Two-tailed, or one-tailed when indi-
cated, unpaired Student´s t test was used to compare two groups. All statistical descriptions
and number of donors used in each experiment are described in the respective figure legends.
Statistical significance was set at p<0.05. The analysis was performed using GraphPad Prism
software.
Results
Helminth infection and type II environment set differential TAM receptors
and ligands expression pattern in patients with MS
The demographic and clinical characteristics of the 3 clinical groups are summarized in
Table 1. The natural helminth-infected multiple sclerosis cohort (HIMS) shows significantly
higher eosinophilia (1576±250.5 count/mm3, p<0.001) and plasma IgE titers (1667±675.2 IU/
ml, p<0.001) compared with the uninfected MS cohort (278.9±114.5 count/mm3 and 448
±206.2 IU/ml, respectively), confirming the presence of a type II environment response. On
the other hand, a significant reduction of the total leukocyte number, mainly due to decreased
circulating lymphocytes, was observed in the MS cohort compared with the HIMS (p<0.05) or
healthy control (HC) groups (p<0.001), Table 1.
TYRO3, AXL, and MERTK expression profiles were analyzed in circulating leukocytes as
shown by the gating strategy in Fig 1A. We have found a significantly lower percentage (%) of
monocytes (CD11bhighCD4mid) and DCs (CD1chighCD11blow) expressing TYRO3 in patients
with MS compared to HIMS or HC groups (Fig 1B, 1C, 1E and 1F, respectively). The mean
expression level of TYRO3 per cell (indicated as MFI) did not show statistical differences in
monocytes, but this receptor showed a significantly higher level in DCs of patients with HIMS
or HC compared to MS (Fig 1D–1G). Intriguingly, we also observed an increased expression
of TYRO3 in CD4+ T cells of patients from the HIMS cohort (S1A Fig), demonstrating that
type-2 immunity has a broad effect on TYRO3. The concomitant helminth infection in
patients with MS also increased the expression level of AXL in CD1chigh DCs, and notably,
there were more cells (%) expressing high levels of AXL in the HIMS group (Fig 1H–1J). Addi-
tionally, the expression level of MERTK was also increased in DC of HIMS cohort (Fig 1K–
1M). MERTK and AXL are not commonly expressed on CD4+ T cells; however, we found a
clear dichotomy in their expression levels, with CD4+ T cells from the HIMS cohort expressing
MERTK and CD4+ T cells from the MS cohort expressing AXL (S1B and S1C Fig). When we
analyzed the levels of the two known TAM receptor ligands, GAS6 and PROS1, in circulating
CD4+CD11b- T cells, we found a significant increase of GAS6 level as well as the % of CD4+ T
cell expressing GAS6 (Fig 1N–1P), but not differences in PROS1 expression in patients with
HIMS compared with MS or HC (Fig 1Q–1S). Additionally, CD11bhighCD4low monocytes
also showed a significant increase in GAS6 and PROS1 in the HIMS cohort compared with the
MS cohort (S1D and S1E Fig), which could contribute to minimizing the pathological
inflammation.
Concomitant helminth infection induces a significantly lower percentage
of Th17 cells and transcriptional program in patients with MS
To analyze which CD4+ T-helper subsets are expanded after activation, PBMCs were stimu-
lated with anti-CD3 and anti-CD28, and intracellular IL-17+ (Th17), IFN-γ+ (Th1), and IL13+
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or IL-4+ (Th2) staining was assessed at days 7, 10, and 17. The cytokine expression kinetics
was first determined using PBMCs from controls subjects, shown in S2A Fig. The Th17 subset
was significantly expanded in the MS cohort, but unlike these uninfected patients, the HIMS
cohort failed to expand this subset at days 7 and 10 after activation (Fig 2A–2C). We did not
find significant differences in the percentage of IFN-γ+CD4+ T cells among clinical groups at
the same time points (Fig 2D–2F). However, a tendency of higher percentage of double-posi-
tive IFN-γ+IL-17+ T cells was found in the MS cohort (p = 0.0734) vs HIMS at day 10 (Fig 2G
and 2H). Surprisingly, the MS cohort also showed an expansion of IL-13+CD4+ T cells after
activation (S2B Fig) as previously reported by Ochi et al [33]. With regards to IL-4-producing
CD4+ T cells, an evident expansion of the Th2-subset was observed in the HIMS cohort even
though the assay was performed with a lower number of samples (Fig 2I–2J). To better under-
stand if each clinical group promotes a differential transcriptional pattern in sorted CD4+ T
cells, we analyzed a panel of genes involved in the Th17 transcriptional program, cytokines,
and negative regulatory feedback. We used the unstimulated HC group as reference and com-
pared activated vs non-activated cells within and between MS and HIMS groups (Fig 2K).
Interestingly, a differential gene expression pattern with higher AHR, RAR-α, LXR-α and
MERTK and decreased SGK1, IL-22, and IL-17 transcripts were observed in the HIMS group
when compared with the MS group at the basal level. Furthermore, the prominent Th17 profile
(IL-17, IL-22, SGK1, and IRF4) was expanded in the MS cohort after activation. In contrast,
the HIMS group showed a lower expression of the transcriptional hallmarks of Th17 cells
upon activation. Similarly, we observed a lower, but not statistically significant, level of IFN-γ
in the HIMS group when compared with the MS group.
Factor analysis of mixed data shows that the differential expression of
TAM components explains and contributes to the segregation of both
cohorts of patients
In order to correlate the differential expression of the TAM axis with other clinical variables,
we performed a factor analysis of mixed data (FAMD) dimensionality reduction approach
grouping the expression of TAM receptors and ligands of each leukocyte population
(CD11bhigh, CD1chigh, and CD4+) with the T-helper subsets, disability score, age, eosinophils,
IgE titer, as well as total leukocyte and lymphocyte numbers. The distribution map shows how
the major informative dimensions (Dim1 and Dim2) explain most of the variance and sepa-
rately segregate patients with MS from those with HIMS (Fig 3A). The individual contribution
of each variable to dimensions indicates that TYRO3 and MERTK expression in CD1chigh
DCs, and GAS6 ligand on CD4+ T cells and monocytes CD11bhigh are responsible for most of
the variability for Dim1 and are strongly associated with the segregation of the HIMS cohort
(Fig 3B). When we performed a hierarchical clustering analysis to reveal the interaction
among variables and patients, we observed that almost 100% of the HIMS cohort merged in
one cluster while the MS cohort can be segregated to at least two clusters (Fig 3C), indicating a
Fig 1. Helminth infection differentially modulates TAM receptor and their ligands expression in patients with MS and type 2 environment. A)
Representative dot plots showing the three main sub-populations of mononuclear cells based on the expression of CD11b, CD4, and CD1c. TYRO3, AXL,
and MERTK expression were evaluated in circulating monocytes (CD11bhighCD4mid) and DCs (CD1chighCD11blow) of patients with MS, patients with
HIMS, and healthy controls by flow cytometry. B-G) The percentage of TYRO3-positive as well as the mean fluorescent intensity (MFI) of the receptor on
monocytes (B, C, and D) and DCs (E, F, and G) are graphed. H, I, and J) The percentage of AXLhigh as well as the MFI of the receptor on DCs are shown.
K, L, and M) The expression of MERTK on DCs is shown as both percentage and MFI. N, O, and P) The percentage of circulating CD4+ T cell expressing
GAS6 as well as its MFI are shown. Q, R, and S) The percentage of circulating CD4+ T cell expressing PROS1 and its MFI are shown. Data is presented as
a pool of independent samples included in the specific staining (Control N = 21–31; MS N = 10–27; and HIMS N = 11–16). One-way ANOVA with a
Fisher post hoc test was performed to determine statistical significances, �p<0.05 ��p�0.01 ����p�0.001. MS = multiple sclerosis, HIMS = helminth-
infected multiple sclerosis.
https://doi.org/10.1371/journal.ppat.1009176.g001
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more complex interaction among components and patients. The variables that are over the
expected average contribution (indicated as a dashed line) are considered as important con-
tributors, and they could be useful for future analysis.
CD4+ T cells from the HIMS cohort promote enhanced negative feedback
on DCs that is dependent on the GAS6/TAM axis
Negative feedback from adaptive to innate immunity, particularly at the level of the T cell-DC
interface, has emerged as a powerful mechanism to control the magnitude of the immune
response [27]. Therefore, we compared the activation profile of DCs when they were chal-
lenged with sorted CD4+ T cells (1:5 ratio) from patients with MS, patients with HIMS, and
HC, respectively, in a MLR assay as previously reported [27]. DCs were differentiated from
CD14+ monocytes of HC for 7 days and then co-cultured with sorted heterologous CD4+ T
cells from each clinical group for 72 hours. CD4+ T cells from patients with HIMS induced
lower levels of the co-stimulatory molecules CD80, CD86, and CD40 on DCs when compared
with the levels induced by CD4+ T cells from patients with MS (Fig 4A–4C). We did not detect
significant differences in HLA-DR expression among clinical groups. These results highlight
that CD4+ T cells from patients with HIMS actively engage immune-regulatory pathways.
Since GAS6 was increased in CD4+ T cells at basal levels in patients with HIMS, and could
be an important contributor for the negative feedback at the T-cell-DC interface, we blocked
this ligand in an MLR assay. Our results showed that under GAS6 blockade, CD4+ T cells from
patients with HIMS enhanced the expression of the three co-stimulatory molecules CD80,
CD86, and CD40 on DCs (Fig 4D–4F), indicating the critical role of this ligand as the negative
feedback signal for this cohort. The anti-GAS6 treatment has differentially impacted co-stimu-
latory markers when using CD4+ T cells from HC and MS groups (S3A–S3C Fig).
GAS6 expression is increased in CD4+IL-10+ in comparison with CD4+IL-
17+ cells of the HIMS cohort and restrains the development of the Th17
subset
Immune pathology frequently arises when critical checkpoints fail to be engaged during the
inflammatory response, inducing unbalanced activation. We found first that both PROS1 and
GAS6 ligands were upregulated after activation, compared to the baseline of non-stimulated
CD4+ T cells, independent of the cohorts (S4A and S4B Fig). Intriguingly, patients with HIMS
condition showed higher levels of GAS6 in acutely isolated CD4+ T cells, but after 10 days
post-activation, the MS group maintained higher levels of both ligands in the Th17 subset
compared with the HIMS cohort (Fig 5A and 5B). Similarly, CD4+IL-10+ cells were also
increased and positively correlated with the Th17 subset (Fig 5C and 5D, r = 0.69; p<0.01 and
S4C Fig) within the MS cohort, which denotes robust compensatory mechanisms that are
Fig 2. Concomitant helminth infection induced a significantly lower percentage of Th17 cells and transcriptional program in patients with
MS. A) Representative dot plot showing CD4+IL-17+ cells, based on the isotype control gating on the left. B and C) The percentage of double
positive cells at day 7 and 10, post activation with anti-CD3/CD28, are graphed. D) Representative dot plot showing CD4+IFNγ+ gate, based on the
isotype control. E and F) The percentage of double positive cells after 7, and 10 days post-stimulation, are shown. G and H) Representative dot plot
and the percentage of IL-17+IFNγ+ double positive in CD4+ T cells at day 10 after stimulation in the three clinical groups are shown. I and J)
Representative dot plot showing the percentage of CD4+IL-4+ T cells, based on the isotype control, after 17 days post-stimulation, and the
independent samples analyzed. K) Heat map showing relative mRNA expression profile of Th17 lineage-specific and related genes in stimulated vs
non-stimulated T cells of MS and HIMS cohorts. All relative expression referenced the non-stimulated healthy control for basal expression levels
(equal 0). The expression levels of indicated gene were evaluated by qPCR and referred as 2^dCT. EF1A1 was used as the housekeeping gene. The
numbers in the heat map indicate the mean value of at least 4 independent samples. Data is presented as a pool of independent samples included in
the specific assay (Control N = 4–23; MS N = 6–22; and HIMS N = 4–12). One-way ANOVA with a Fisher post hoc test was performed to
determine statistical significance, �p<0.05 ��p�0.01 ����p�0.001. MS = multiple sclerosis, HIMS = helminth-infected multiple sclerosis.
https://doi.org/10.1371/journal.ppat.1009176.g002
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insufficient at controlling the pathogenic response in these patients. Interestingly, when com-
paring GAS6 expression between CD4+IL-10+ and Th17 cells, a significantly higher GAS6 lev-
els in the IL-10+ than IL-17+ cells was observed only in the HIMS group, denoting that the
balance of this ligand between these effector cells is critical to keep pathological cells under
control (Fig 5E). The TAM ligands require binding to PtdSer and cellular contact in order to
activate the TAM receptors, and we have recently shown that activated T cells transiently
expose this phospholipid on their surface (27). To test if this mechanism has an active role in
Th17 induction, a PtdSer-binding competitor, Annexin V (AnnV) was added during CD4
stimulation and expansion. The number of clustering cells was reduced in the presence of
AnnV during the first 3 days of culture; however, it promoted an increased expression of
Fig 3. Factor analysis of mixed data shows that the differential expression of TAM components explains and contributes to the segregation of both cohorts of
patients. To analyze the similarity and relationship among 24 variables studied in both MS and HIMS cohorts, we have performed the factor analysis of mixed data
(FAMD) dimensionality reduction approach. We have included TAM receptors and ligands expression in each leukocyte population (CD11bhigh, CD1chigh, and CD4+),
the percentage of T-helper cells, score disease (EDSS), age, eosinophils, IgE titers, and total leukocyte and lymphocyte numbers. A) Individual Factor Map shows the
distribution of the two most informative dimensions (Dim1 and Dim2) that explain the 39.4% of variance. Patients from MS group were highlighted in light-blue (1–29)
and HIMS cohort (30–47) in purple for visualization. B) The bar graph indicates the top 20 individual variables that contribute to segregate Dim 1. The red dashed line
indicates the expected average contribution. Variables over the cut-off would be considered as important contributors. C) Hierarchical clustering analysis shows that the
cluster n˚3 separately groups most of HIMS patients while cluster n˚2 groups the majority of MS patients. The arrowheads show some patients of MS (5 and 11) or
HIMS (31 and 39) clustering differentially.
https://doi.org/10.1371/journal.ppat.1009176.g003
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CD44, higher percentage of CD4+ IL-17+ cells after 7 days of activation (S4D and S4E Fig), as
well as increased IL-17 and IFN-γ RNA transcripts at day 5 (Fig 5F and 5G). Similarly, the use
of a GAS6 blocking antibody increased the mRNA level of IL-17, IFN-γ, cMAF, HIF1-α, and
IRF4 in activated CD4+ T cells from HC (Fig 5H–5J). Furthermore, blocking GAS6 in acti-
vated CD4+ T cells from the HIMS group also led to an increased expression of IL-17 and
IFN-γ (Fig 5K and 5L). In the same sense, treatment with 50nM of hrGAS6 dramatically
reduced not only IL-17 and IFN-γ, but also IL-22, cMAF, SGK-1, HIF1-α and AHR expression
in activated CD4+ T cells from patients with MS (Fig 5M–5S respectively). These results sug-
gest that GAS6 and PtdSer binding are critical signals to control not only T cell activation but
also of IFN-γ and Th17 expansion in a cell contact-dependent manner. Altogether, our results
suggest that GAS6 tempers not only an innate immune response but also regulates Th17 devel-
opment in an autocrine/paracrine way.
Discussion
Multiple factors may be responsible for, or contribute to, the increased incidence and preva-
lence of MS in recent decades globally [7]. However, since these population changes have
Fig 4. CD4+ T cells from patients with MS and concomitant helminth infection induced lower DCs activation that
is GAS6-dependent. Mixed lymphocyte reaction (MLR) assay was performed by co-culturing monocyte-derived DCs
from healthy controls with heterologous sorted CD4+ T cells from patients with MS and HIMS at a 1:5 ratio for 72
hours. Activation status of DC was evaluated by measuring surface levels of co-stimulatory molecules. A, B, and C)
Relative expression levels of CD80 (A), CD86 (B), and CD40 (C) on CD11c+ DC cells after MLR assay. Expression levels
were calculated relative to basal expression of DCs alone. D, E, and F) Blocking antibody against GAS6 (2 μg/mL) or its
corresponding isotype was added in the MLR assays, and relative expression levels of CD80 (D), CD86 (E), and CD40
(F) on CD11c+ cells was calculated. The MLR assay was assessed employing 4–7 independent monocyte-derived DCs
co-cultured with sorted CD4+ T cells from at least 4–6 different patients of each clinical group. Paired t-test was
performed for each activation marker and statistical significances are indicated as �p<0.05 ��p�0.01. MS = multiple
sclerosis, HIMS = helminth-infected multiple sclerosis.
https://doi.org/10.1371/journal.ppat.1009176.g004
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occurred over a rather short period of time, genetic factors are an unlikely cause, indicating
that the environment strongly influences MS risk. One of these environmental factors is
known as the biome depletion theory, which states that the loss of species diversity from the
ecosystem of the human body in modern industrialized countries leads to immune dysregula-
tion and a subsequent increase in the prevalence of chronic inflammatory-associated diseases
[34]. This paradigm appreciates the importance of an array of microbes and helminths as
essential for immune system development and regulation [34,35]. In support of this theory,
Correale et al. have previously shown that well-tolerated natural helminth infection protect
against worsening of MS symptoms in humans. Moreover, since anti-parasitic treatment
results in the worsening of helminth-infection symptoms, its use leads to a significant increase
in clinical and radiological MS activities, an increase in the number of IFN-γ and IL-12 pro-
ducing cells, and a reduction in regulatory signals after three months of anti-helminths treat-
ment [23]. Type 2 immune responses are elicited to clear parasitic helminth infections;
however, helminths have also evolved and acquired a variety of immunotolerant regulatory
mechanisms that manipulate immune development and function to ensure their survival
[36,37]. Deciphering these regulatory mechanisms may provide new therapeutic insights for
allergic and autoimmune disorders, metabolic syndrome, and chronic low-grade inflamma-
tion [38]. Even though numerous studies support helminth therapy as a promising concept
[16,34,38], we still need a better understanding of the dominant immunological mechanisms
and the types of helminths that can be used for therapy, which will require additional preclini-
cal studies as well as systematic clinical trials.
In the present work, we showed how natural helminth infections enhanced the negative
regulatory axis of TAM receptors and their ligands in patients with MS and could be essential
for controlling the inflammatory response. We have previously observed that TYRO3 is
increased on human monocyte-derived DC of helminth-infected subjects [28]. Here, we
showed that parasite infection primes innate and adaptive immune cells with an increased
expression of the TAM axis. Schistosome eggs-derived antigen triggers a tolerogenic response
by decreasing CD40, CD80, and CD86 co-stimulatory markers on DCs [39], and our findings
reveal that CD4+ T cell from patients with HIMS also induced lower DC activation in a GAS6-
dependent manner. We postulate that the helminth-type 2 environment hijack the TAM sig-
naling to temper innate immune response and consequently reduce the development of patho-
genic Th1/Th17 responses (Fig 6, proposed model). The multivariate analysis supports the
relevance of the TAM axis since most of the variability could be explained by the differential
expression of TYRO3, GAS6, and MERTK in innate immune cells to discriminate between the
HIMS and MS cohorts.
Emerging data on Th17-mediated diseases suggest that different types of IL-17-producing
T cells exist in vivo, and these can be divided into pathogenic or non-pathogenic Th17 cells
Fig 5. GAS6 expression is higher in CD4+ IL-10+ cells than in CD4+IL17+ cells and modulates Th17 development in HIMS. A and B) Expression levels of PROS1
and GAS6 in CD4+ IL-17-expressing cells, measured as MFI, are shown. Independent data for each specific staining are shown, and the negative threshold is indicated
as a black dash line. The baseline expression of non-stimulated CD4+ T cells is indicated as a blue dash line. C and D) The percentage of CD4+IL10+ cells was positively
correlated with the percentage of Th17 subset. E) Comparison of GAS6 expression levels between IL-10+ and IL17+ CD4+ T cells within each clinical group. F-I) Sorted
CD4+ T cells from healthy controls were activated and expanded with anti-CD3/CD28 during 5 days in the presence of AnnV (1 μg/mL), a competitor for
phosphatidylserine binding with TAM ligands, or blocking anti-GAS6 (2 μg/mL) antibody; IL-17 and IFNγ mRNA expression were evaluated by quantitative PCR
(qPCR). J) Transcription factor genes related to the Th17 subset (IRF4, LXRα, cMAF, AHR and HIF1α) were also evaluated in stimulated CD4+ T cells under anti-GAS6
treatment by qPCR. K and L) mRNA level of IL-17 and IFNγ were evaluated in activated CD4+ T cells from HIMS group after blocking GAS6. M-S) CD4+ T cells from
controls and patients with MS were activated with anti-CD3/CD28 and treated with 50 nM of recombinant human GAS6 every 2 days during 5 days and IL-17 and
IFNγ, IL-22, cMAF, SGK1, HIF1α, and AHR were evaluated by qPCR. Correlation was assessed by Spearman test. Flow cytometry data is presented as a pool of
independent samples included in the specific staining (Control N = 4–14; MS = 6–15; HIMS = 6–10). qPCR was performed with at least 5 independent HC, 3 of MS,
and 3 of HIMS donors. One-way ANOVA with a Fisher post hoc test was used in A-D and statistical significances are indicated as �p<0.05 ��p�0.01. One-tailed paired
t-test was used to compare blocking conditions. MS = multiple sclerosis, HIMS = helminth-infected multiple sclerosis.
https://doi.org/10.1371/journal.ppat.1009176.g005
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depending on the transcriptional program and functional properties [40,41]. Furthermore, the
plasticity of this subset is evident in chronic and pathological immune responses as well as res-
olution [42]. The ability of parasites to defy host immunity reflects their masterful manipula-
tion of the immune system by affecting CD4+ T cell differentiation, Treg cell induction, B cell
isotype switching, and Breg cell induction [16], which in turn determine the effector cell
responses of the host. Here, we reported that the HIMS condition resets CD4+ T cells pro-
gramming and redirects the immune response by increasing expression of IL-4, RAR-α, AHR,
LXR-α and MERTK along with decreased SGK1, IL-22, and IL-17 when compared with the
MS cohort. These results support the hypothesis that controlled helminths coexistence
enhances negative regulatory circuits to mitigate the inflammatory response. The number of
patients associated with a particular species of helminth in this study is too low for a conclusive
correlation between helminth species and modulatory effect. Nonetheless, the species listed in
this report could be useful for the design and planning of future studies using controlled
Fig 6. Helminth-induced type 2 immunity enhances regulatory TAM/GAS6 signaling to dampen Th17 pathological responses in multiple sclerosis. The host type
2 immune response is elicited to clear parasitic helminth infections; however, the co-evolution of these parasites has promoted a variety of mechanisms to oppose and
redirect immune responses by manipulating immune cell programming and function. Integrating our results with the current knowledge, we propose that
gastrointestinal (1) helminths infections can enhance the regulatory axis of TAM receptors (TYRO3, AXL, and MERTK) in peripheral blood (2) CD11bhigh and
CD1chigh cells, and their ligand GAS6 in CD4+ T cells of patients with MS. This negative regulatory pathway could be essential for dampening co-stimulatory signals
(CD40, CD80, and CD86) of antigen-presenting cells and controlling the pathological Th17 (pTh17) response at secondary lymphoid organs (3). The active chronic
infection resets T helper response toward Th2/regulatory signals, limiting pathological Th17 (pTh17) effector response. This reprogramming of CD4+ T cells and GAS6
signaling under a helminth-induced type 2 environment could be essential for maintaining the balance between CD4+ IL-10+ and Th17 cells and reducing inflammatory
IL-17 and IFNγ signals in the central nervous system (4). In summary, GAS6 tempers not only the innate immune response but also regulates Th17 development in an
autocrine/paracrine manner.
https://doi.org/10.1371/journal.ppat.1009176.g006
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helminth infection in patients with MS (S2 Table). Identifying the helminth species or their
products for future therapy trials is the major challenge. Specific eligibility criteria need to be
addressed when evaluating prospective therapy, such as feasible domestication, controlled
exposure to population, and positive cost/benefit ratio [16,34].
Previously we have shown that T cell-derived PROS1 from healthy volunteer samples play a
critical role in the negative regulation of DC activation [27]. Despite structural homology
between GAS6 and PROS1, both ligands have distinct affinities for the TAM receptors and are
also differentially expressed in various cell types [43]. The functions of GAS6 seem to be lim-
ited to those caused by activation of the TAM receptors while PROS1 has both TAM receptor-
dependent and independent activities [24]. GAS6 plays a critical role as an immunoregulatory
signal at the interface of innate and adaptive immunity, and our findings suggest that the bal-
ance of this ligand between regulatory and effector cells is critical to restrain pathological Th17
cells, as observed under HIMS condition. Conversely, the higher inflammatory milieu in the
MS cohort keeps high numbers of IL-17+ and IL10+ but without contraction, supporting the
idea that true suppressor CD4+IL10+ also depends on GAS6 signaling. When GAS6 was neu-
tralized during expansion of the Th17 subset, we found increased expression levels of IL-17,
IFN-γ, cMAF, IRF4, and HIF1-α. In the same sense, the treatment with recombinant GAS6
reduced the transcript levels of IFN-γ and the signature of pathogenic Th17 cells induced by
CD4+ T cells from MS group. These results demonstrate the role of GAS6 in controlling Th17
expansion and the transcriptional program and plasticity of the Th17 subset (Fig 6, proposed
model).
Limitations of this study included the transversal analysis and limited cell numbers. The
transversal analysis was only capable of providing a snapshot of the dynamic immune response
and pathological course. The cell numbers recovered from each sample varied across patients
and precluded the performance of all assays for every recruited patient.
In agreement with our results, it has been shown that GAS6 enhances the suppressive activ-
ity of Tregs in vitro and in vivo [44]. Furthermore, the exogenous administration of GAS6 into
the brain of wild-type mice had a therapeutic effect in improving the recovery from damage
after cuprizone withdrawal along with a beneficial effect on the clearance of cellular and mye-
lin debris, promoting remyelination and maturation of oligodendrocyte progenitor cells [45].
On the other hand, loss of GAS6 and AXL signaling while undergoing cuprizone challenge
results in extensive axonal damage, prolonged neuroinflammation, severe demyelination, a
greater reduction in oligodendrocytes number, and an overactivation of microglia and motor
deficits [46]. When MOG-induced experimental autoimmune encephalomyelitis was per-
formed in Gas6−/− mice, worse clinical scores, delayed recovery from damage, a higher
expression of pro-inflammatory molecules, and a significant increase of macrophages infiltra-
tion were observed. In contrast, the direct intracerebral delivery of GAS6 is protective with evi-
dence of less demyelination and enhanced remyelination relative to controls [47].
Interestingly, a recent study also showed that the intra-articular adenoviral delivery of TAM
agonists reduced joint pathology in a murine model of rheumatoid arthritis [48]. Therefore,
GAS6-TAM signaling is a key modulator not only for the homeostatic immune response but
also to promote the remyelination process, though this has only been shown in animal models.
Even though very few studies are available, autopsy studies on patients with MS revealed that
soluble AXL and MERTK can act as decoy receptors and block GAS6 binding, resulting in dys-
regulation of protective GAS6-mediated signaling, leading to prolonged lesion activity [49].
In conclusion, our work substantiates the hypothesis that enhancing the TAM axis in a
manner similar to helminth infection could be a promising treatment for autoimmune dis-
eases by mitigating the detrimental inflammatory response and empowering regulatory signals
to restore tissue homeostasis.
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Supporting information
S1 Table. List of Primers sequences.
(DOCX)
S2 Table. Number of Patients with MS and natural helminth infection discriminated by
spp of helminth and IFN-β treatment.
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S1 Fig. Differential TAM expression in CD4+ population and GAS6 and PROS1 in
CD11bhigh monocytes of patients with HIMS compared with patients with MS. A-C)
TYRO3 and MERTK are preponderantly expressed in CD4+ T cells of HIMS while AXL-
expressing lymphocytes are increased in MS patients. D-E) GAS6 and PROS1 expression in
CD11bhighCD4mid monocytes are graphed as MFI relative to isotype. Data is presented as a
pool of all independent samples included in a specific staining of each assay (Control N = 21–
31; MS = 11–27; HIMS = 11–16). One-way ANOVA with a Fisher post hoc test was performed
to determine statistical significances, �p<0.05 ��p�0.01 ���p�0.005 ����p�0.001.
MS = multiple sclerosis, HIMS = helminth-infected multiple sclerosis, MFI = Mean Fluores-
cence intensity.
(TIFF)
S2 Fig. Kinetics of intracellular cytokine production by CD4+ T cells after TCR stimula-
tion. A) The intracellular production of IL-17, IFNγ, and IL-4 in CD4+ T cells was determined
by stimulating PBMCs from healthy subjects with 1ug/mL of plate bound anti-CD3 and solu-
ble anti-CD28 at different time points. To analyze the level of intracellular cytokines, cells were
harvested at 7, 10 and 17 days post stimulation plus a reboost with ionomycin and PMA for
the last 4 hours before harvesting. Viability staining with Fixable viability dye AF450 was
included. B) The percentage of IL-13+ cells in CD4+ T lymphocytes after 10 days of stimulation
in the three clinical groups are shown (Control N = 13; MS = 16; HIMS = 7). The threshold for
the positive signal of cytokines was determined with the corresponding isotype. One-way
ANOVA with a Fisher post hoc test was performed to determine statistical significances.
MS = multiple sclerosis, HIMS = helminth-infected multiple sclerosis.
(TIFF)
S3 Fig. GAS6 neutralization enhances CD80 but not CD86 expression on DCs after MLR
assay. Mixed lymphocyte reaction (MLR) assay was performed by co-culturing monocyte-
derived DCs from HCs with heterologous sorted CD4+ T cells from patients with MS or HCs
at a 1:5 ratio during 72 h. The activation status of DCs was evaluated by measuring surface lev-
els of co-stimulatory molecules. A-C) Relative expression levels of CD80 (A), CD86 (B) and
CD40 (C) on CD11c+ referred to that of DCs alone. Blocking antibody against GAS6 (2 ug/
mL) or its corresponding isotype were used. The MLR assay was assessed employing 4 inde-
pendent monocyte-derived DCs co-cultured with sorted CD4+ T cells from at least 4 different
donors of each group. Paired t-test was performed for each activation marker and statistical
significances are indicated as �p<0.05 ��p�0.01. MS = multiple sclerosis, Control = Healthy
control, HC = healthy control.
(TIFF)
S4 Fig. PROS1 and GAS6 expression in activated CD4+ T cells, and how blocking PtdSer
leads to increased CD44 expression and IL-17 production. A-B) The levels of PROS1 and
GAS6 were evaluated on total CD4+ T cells after 7 days post-stimulation (Control N = 4–19;
MS = 6–23; HIMS = 6–10). The negative threshold is indicated as a black dash line. The basal
expression of non-stimulated CD4+ T cells is indicated as blue dash line. C) Representative dot
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plot showing the percentage of CD4+ IL-10+ T cells compared to the isotype control after 10
days post-stimulation. D-E) The activation status of CD4+ T cells in the presence of AnnV (1
ug/ml), a competitor for PtdSer binding with TAM ligands, was evaluated in control PBMCs
stimulated with 1ug/mL of anti-CD3 and anti-CD28 after 7 days (N = 4). D) CD44 levels on
CD4+ cells and E) intracellular levels of IL-17 were determined by flow cytometry. The expres-
sion levels of CD44 and IL-17 are referred to fluorescent minus one as negative signal.
Annexin V was added from day 0 of stimulation and at day 3 of culture. One-way ANOVA
with a Fisher post hoc test was performed to determine statistical significances. Paired t-test
was performed for D and E, and statistical significances are indicated as �p<0.05.
(TIFF)
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